Omalizumab in Severe Asthmatics With Food Allergy
Conditions: Food; Allergy, Anaphylactic Shock; Asthma in Children Interventions: Biological: Omalizumab Sponsors: Bambino Ges ù Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Comparative Bioavailability of Intranasal Epinephrine
Conditions: Anaphylaxis; Anaphylactic Reaction Interventions: Drug: A: Epinephrine injection; Drug: B: FMXIN002 3.6mg; Drug: C: FMXIN002 4.0mg Sponsors: Nasus Pharma; Hadassah Medical Organization; Medistat Ltd., Israel; Pharma Medica Research, Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
EPAP, Interviewstudy
Conditions: Food Allergy; Food Allergy Peanut; Allergy; Anaphylactic Shock Sponsors: Charite University, Berlin, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
Conditions: Allergic Reaction; Hypersensitivity; Perioperative Complication; Anaphylaxis; Anaphylactic Reaction; Immediate Hypersensitivity; Hypersensitivity, Drug Interventions: Diagnostic Test: Full dose DPT with propofol; Diagnostic Test: Full dose DPT with ketamine; Diagnostic Test: Full dose DPT with etomidate; Diagnostic Test: Full dose DPT with midazolam; Diagnostic Test: Full dose DPT with fentanyl; Diagnostic Test: Full dose DPT with sufentanyl; Diagnostic Test: Full dose DPT with alfentanil; Diagnostic Test: Full dose DPT with remifentanil; Diagnostic Test: Full dose DPT with rocuronium; Diagnostic Test: Full dos...
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
